Bausch Health achieved its seventh consecutive quarter of year-over-year growth, reporting Q4 revenue of $2.56 billion, up 6%. Adjusted net income increased to $430 million, while GAAP net income reached $93 million. The company showed strong performance in the Solta Medical and Bausch + Lomb segments, with significant revenue growth.

Bausch Health announced its third quarter 2024 financial results, achieving a 12% increase in consolidated revenues to $2.51 billion and a 10% rise in Adjusted EBITDA to $909 million. The company also raised its full-year 2024 guidance.

Bausch Health reported a strong second quarter with an 11% increase in consolidated revenues to $2.40 billion and a 10% increase in adjusted EBITDA to $798 million. The company also raised its full-year revenue and adjusted EBITDA guidance, reflecting confidence in its growth strategy and product portfolio.

Bausch Health announced strong first quarter 2024 results with revenues of $2.15 billion, up 11% on a reported basis and 8% organically. All segments showed year-over-year revenue growth. The company reaffirmed its full-year revenue and adjusted EBITDA guidance.

Bausch Health reported a 10% increase in fourth-quarter revenues, reaching $2.41 billion, and a net loss attributable to Bausch Health of $39 million. Full-year revenues were $8.76 billion, up 8% from the previous year, with adjusted EBITDA at $869 million for the quarter, up 6% from previous year.

Bausch Health announced its third-quarter 2023 financial results, with revenue of $2.24 billion, up 9% on both a Reported and Organic basis. All segments showed year-over-year revenue growth. The company's Adjusted EBITDA was $830 Million, up 8%. They also received FDA approval for CABTREOTM and provided updated full-year Revenue and Adjusted EBITDA guidance.

Bausch Health reported a strong second quarter with revenue of $2.17 billion, up 10% reported and 11% organic. GAAP net income attributable to Bausch Health Companies Inc. was $26 million, and adjusted EBITDA was $727 million, up 4%. The company raised its full-year revenue outlook and reaffirmed its adjusted EBITDA guidance.

Bausch Health reported a 1% increase in first-quarter revenue to $1.94 billion, with organic revenue growth of 4%. The company is progressing its mid- and late-stage pipeline and reaffirmed its full-year guidance for Bausch Health (excl. B+L) and provided full year consolidated guidance.

Bausch Health reported flat revenue of $2.2 billion for the fourth quarter of 2022 compared to the fourth quarter of 2021, but saw a 4% increase organically. For the full year, revenues were $8.1 billion, a 4% decrease reported, but a 2% increase organically. The company reduced debt by $464 million in the fourth quarter and provided 2023 guidance for Bausch Health (excl. B+L).

Bausch Health reported a revenue of $2.046 billion for Q3 2022, a 3% decrease compared to Q3 2021, but showed a 2% increase on an organic basis. The company highlighted top-line improvements in several segments and a successful debt exchange offer that reduced debt by $2.5 billion. They have updated full year guidance.

Bausch Health reported revenues of $1.967 billion for Q2 2022, a 6% decrease compared to Q2 2021. The company intensified its focus on the Bausch Pharma and Solta businesses, advanced debt paydown through open market repurchases, and is committed to strategic alternatives.

Bausch Health Companies Inc. announced its first-quarter 2022 financial results. The company reported revenues of $1.918 billion and a GAAP net loss of $69 million. Adjusted EBITDA was $732 million. Bausch + Lomb commenced trading under the ticker "BLCO" following its IPO.

Bausch Health Companies Inc. reported Q4 2021 revenues of $2.196 billion and GAAP net income of $69 million. The company's full-year revenue grew by 5% compared to the previous year, driven by key products gaining market share and new product launches. Bausch Health has filed public registration statements for Bausch + Lomb and Solta and is prepared to launch both IPOs.

Bausch Health reported third-quarter 2021 revenues of $2.111 billion, GAAP net income of $188 million, and adjusted EBITDA of $885 million. The company is advancing its strategic alternatives process, expecting to launch the Solta Medical IPO in December 2021 or January 2022, followed by the Bausch + Lomb IPO approximately 30 days later.

Bausch Health Companies Inc. announced its second-quarter 2021 financial results, demonstrating impressive overall company growth as businesses continue to recover from the COVID-19 pandemic. Total reported revenues were $2.100 billion, an increase of 26% compared to the second quarter of 2020. The company reported a GAAP net loss of $595 million and Adjusted EBITDA of $826 million.

Bausch Health reported a slight increase in revenue for Q1 2021, but experienced a significant net loss due to goodwill impairment charges. The company is progressing with the planned separation of its eye health business, Bausch + Lomb, and reaffirmed its full-year revenue and adjusted EBITDA guidance.

Bausch Health reached an agreement with the Icahn Group, appointing Brett Icahn and Steven Miller as new independent directors to the Board, effective mid-March 2021. The Icahn Group, owning approximately 7.83% of the Company’s outstanding common stock, agreed to vote in favor of the Board’s nominees at the 2021 Annual Meeting.

Bausch Health's third-quarter 2020 results demonstrated recovery from the COVID-19 pandemic with total company reported revenue growing 28% sequentially from the second quarter. The company reaffirmed its 2020 full-year revenue and adjusted EBITDA guidance ranges.

Bausch Health reported revenues of $1.664 billion for Q2 2020, a decrease of 23% compared to Q2 2019, primarily due to the impact of the COVID-19 pandemic. The company had a GAAP net loss of $326 million and an adjusted EBITDA of $622 million. They also narrowed their 2020 full-year revenue and adjusted EBITDA guidance ranges.

Bausch Health Companies Inc. announced its first-quarter 2020 financial results. Revenues were $2.012 billion, and the GAAP net loss was $152 million. The company lowered its full-year revenue and Adjusted EBITDA guidance ranges due to the COVID-19 pandemic.

Bausch Health Companies Inc. announced its fourth-quarter and full-year 2019 financial results, demonstrating consistency and durability with revenue growth and strong performance in the Salix and Bausch + Lomb/International segments. The company delivered total company reported revenue growth of 5% in the fourth quarter and 3% for the full year of 2019.